Αρχική World News A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across... World News A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC Από Ogkologos - 5 Φεβρουαρίου, 2025 944 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction... 17 Νοεμβρίου, 2023 Can Eating Grilled or Charred Foods Cause Cancer? 10 Ιανουαρίου, 2023 Breast cancer mortality down 66% in 20 years 13 Ιουνίου, 2023 FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer 2 Αυγούστου, 2021 Φόρτωση περισσοτέρων HOT NEWS Droplet Transmission vs. Airborne… What’s the difference? CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some... ESMO Announces Results of 2025 Elections A peek behind the scenes: Just how are our funding decisions...
